April 28, 2025 06:36 AM EDTUpdated 09:00 AM

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Elizabeth Cairns

Senior biopharma journalist

GSK’s Jemperli has maintained its outstanding efficacy among patients with a particular form of rectal cancer. Every one of 49 patients with mismatch repair deficient …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

Exclusive: Can AI replace animal testing? A new biotech launches to find out

European regulators recommend new drugs from Vertex, Amgen and Jazz

Keytruda around head and neck cancer surgery cuts chance of disease coming back

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Senior biopharma journalist

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer